Editor-in-Chief, Deputy Editor 2017-2019

 

Editor-in-Chief:

Tom MOREELS

 

Deputy Editor:

Nicolas LANTHIER

 

Letters



Autoimmune Hepatitis with anti SLA antibodies


Price: €10,00

Autoimmune hepatitis (AIH) is a chronic progressive liver disease characterized by female predominance, hypergammaglobulinemia, specific autoantibodies, an association with HLA DR3 & DR4 and a favourable response to immunosuppressive treatment. The diagnosis of AIH includes a combination of clinical, laboratory and histological features (1). Three subtypes of AIH have been proposed based on the different immunomarkers. Type I AIH, the most common form of the disease is associated with antinuclear (ANA) and anti smooth muscle (SMA) antibodies, affects all age group and is associated with HLA DR3 and DR4 (2). Type 2 AIH characterized by the presence of anti-liver kidney microsomal-1(LKM1) antibodies, is associated with HLA DRB1 and has a poorer outcome (2,3). Type 3 AIH defined by the presence of antisoluble liver antigen/liver pancreas antibodies (anti- SLA/LP), is a rare condition, representing less than 10% of all AIH (4-6). [Product Details...]



Endoscopic and ultrasonographic diagnosis of intramural small bowel hematoma apparently caused by warfarin


Price: €10,00

Nontraumatic intramural hematoma in the small bowel is uncommon, but has been reported to occur in the jejunum, ileum and duodenum in descending order of frequency (1). For diagnosis of this condition, endoscopy, computed tomography or ultrasonography are usually sufficient (1,2). Here we describe the endoscopic and ultrasonographic findings of a patient who had intramural small bowel hematoma apparently caused by warfarin. A 66-year-old woman presented at our hospital’s emergency department with abdominal pain, fever, anorexia and melena. Her past medical history was notable for prosthetic mitral valve, hypertension, coronary artery disease, facial paralysis and diabetes mellitus. Her current medications included warfarin (7.5 mg/day), aspirin, acarbose, gliclazide, spironolactone and beta blockers. Physical examination revealed tenderness and a palpable mass in the epigastric region. Digital rectal examination confirmed melena. [Product Details...]



Ileocolonic involvement of follicular small cell lymphoma : A Rare Entity


Price: €10,00

Follicular lymphoma (FL) is the most common of the indolent lymphomas. On the other hand, FLs occur seldom in the gastrointestinal tract (GIT), representing only 1-3% of all GIT B-cell non-Hodgkin lymphomas. The most frequent site of involvement is the small intestine, particularly the duodenum and terminal ileum, followed by colon (1). In the literature, only one case of the terminal ileum and colonic involvement of follicular lymphoma has been reported (2). Herein, we report a second case of terminal ileum and colon involvement by a follicular small cell lymphoma. [Product Details...]



Pegylated interferon associated lichen planus at the injection site


Price: €10,00

Pegylated interferon alpha-2b (PEG-IFN) is a formulation of recombinant human interferon conjugated with polyethylene glycol. Compared with standard interferon, pegylated interferon has a longer half-life and superior antiviral efficacy in the treatment of hepatitis C. So it has become the standard therapy with ribavirin for the treatment of chronic hepatitis C (CHC) (1). One of the side effects of pegylated interferon is localized inflammatory skin lesions such as eczematous reactions, cutaneous necrosis and vitiligo at the injection site. Herein we report the first case of lichen planus (LP) at the injection site due to pegylated interferon and ribavirin combination therapy. [Product Details...]



Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin : letter to editor


Price: €10,00

Combination of pegylated interferon alpha (PegIFNa) plus ribavirin is currently the standard therapy for patients with chronic hepatitis C (CHC). Sudden hearing loss (SHL) is a rare complication of CHC treatment that is not well documented. We report a case of a 42-yearold Greek man with CHC (genotype 1b) who developed right-sided hearing loss 46 weeks after the initiation of therapy with PegIFNa-2a subcutaneously, at a dose of 180 μg/week, and ribavirin orally, at a dose of 1200 mg/day, for a scheduled period of 48 weeks. Before treatment his clinical examination (including neurologic assessment) was normal and there was no history of previous disease or consumption of any drug or alcohol. Serum levels of glucose, urea, creatinine, electrolytes, lipids, alkaline phosphatase, gamma glutamyltransferase, bilirubin, albumin, ferritin and blood cell count were normal. [Product Details...]


  • «« Start
  • « Prev
  • 1
  • Next »
  • End »»
Results 1 - 5 of 5